Advertisement Genoptix prices secondary public offering - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Genoptix prices secondary public offering

Genoptix has reported the pricing of 2.09 million shares of outstanding common stock being offered by certain existing stockholders to the public at the price of $25.50 per share.

Company will not receive any proceeds from the sale. The offer is expected to close on March 5, 2008.

The offering is being made through an underwriting syndicate led by Lehman Brothers, acting as sole book-running manager. Banc of America Securities and UBS Investment Bank are acting as joint lead managers with Cowen and Company, as co-manager. The selling stockholders have granted the underwriters a 30-day option to purchase up to 313,043 additional shares of common stock.